Gallant closes $18 million Series B to advance its stem cell therapies for pets, led by Digitalis Ventures.
Amount Raised
$18 Million
Round Type
Series B
San DiegoOtherBiotechnologyHealth CareTherapeuticsInvestors
Description
Gallant, an animal health biotechnology company, successfully closed its $18 million Series B financing round. The funding, led by Digitalis Ventures, will accelerate the commercial rollout of its lead product targeting Feline Chronic Gingivostomatitis. This funding also supports a pipeline of therapies for other common diseases in pets. Gallant aims to address the underlying issues rather than merely managing symptoms.
Quick answer
Gallant raised $18 Million in a Series B round, dated June 30, 2025. Investors: NovaQuest Capital Management, Hill Creek Partners, Bold Capital and Digitalis Ventures. Gallant is based in San Diego, California, United States.
- How much did Gallant raise?
- Gallant raised $18 Million in a Series B round on June 30, 2025.
- Who invested in Gallant?
- NovaQuest Capital Management, Hill Creek Partners, Bold Capital and Digitalis Ventures are named as investors in this round.
- What does Gallant do?
- Gallant is a regenerative medicine company pioneering veterinary therapies that restore health at the source.
- Where is Gallant based and how big is it?
- Gallant is based in San Diego, California, United States.
- Who are the decision-makers at Gallant?
- Fundz holds 1 contact at Gallant, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Gallant that raised within 45 days of this round, from Fundz verified event records.
- Eyestem raised $10M (Series B) on August 11, 2025.
- Tevogen Inc. raised $1M (Funding Round) on August 7, 2025.
- Retension Pharmaceuticals raised $15M (Series B) on August 6, 2025.
- Lysoway Therapeutics raised $2.9M (Seed) on August 6, 2025.
- ForCast Orthopedics raised an undisclosed amount (Series A) on August 5, 2025.
- Silexion Therapeutics raised $3.6M on August 1, 2025.
Who to call at Gallant, and when
A new round usually means Gallant is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Gallant raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gallant, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gallant. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gallant raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGallant raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.